 <h1>Mavenclad Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>cladribine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about cladribine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Mavenclad.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cladribine: oral tablet</i></p><p>Other dosage forms:</p><ul><li>intravenous solution</li></ul><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>MalignancyTreatment with cladribine may increase the risk of malignancy. Cladribine is contraindicated in patients with current malignancy. In patients with prior malignancy or with increased risk of malignancy, evaluate the benefits and risks of the use of cladribine on an individual patient basis. Follow standard cancer screening guidelines in patients treated with cladribine.Risk of TeratogenicityCladribine is contraindicated for use in pregnant women and in women and men of reproductive potential who do not plan to use effective contraception because of the potential for fetal harm. Malformations and embryolethality occurred in animals. Exclude pregnancy before the start of treatment with cladribine in females of reproductive potential. Advise females and males of reproductive potential to use effective contraception during cladribine dosing and for 6 months after the last dose in each treatment course. Stop cladribine if the patient becomes pregnant.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, cladribine (the active ingredient contained in Mavenclad) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking cladribine:</p><p>
<i>More common</i>
</p><ul>
<li>Body aches or pain</li>
<li>chills</li>
<li>cough</li>
<li>ear congestion</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>headache</li>
<li>hives, itching, skin rash</li>
<li>hoarseness</li>
<li>irritation</li>
<li>joint pain, stiffness, or swelling</li>
<li>loss of voice</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>redness of the skin</li>
<li>runny or stuffy nose</li>
<li>sneezing</li>
<li>sore throat</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>tightness in the chest</li>
<li>troubled breathing or swallowing</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blurred vision</li>
<li>cough producing mucus</li>
<li>discouragement</li>
<li>dizziness</li>
<li>feeling sad or empty</li>
<li>lack of appetite</li>
<li>loss of interest or pleasure</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>slow heartbeat</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Burning or stinging of the skin</li>
<li>confusion</li>
<li>painful cold sores or blisters on the lips, nose, eyes, or genitals</li>
<li>seizures</li>
<li>stiff neck</li>
<li>vomiting</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, loosening of the skin</li>
<li>chest pain</li>
<li>diarrhea</li>
<li>muscle pain</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>swollen glands</li>
<li>unusual bleeding or bruising</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of cladribine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>difficulty in moving</li>
<li>muscle stiffness</li>
<li>trouble sleeping</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Thinning or loss of hair</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cladribine: intravenous solution, oral tablet</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia, thrombocytopenia, anemia, purpura</p>
<p><b>Common</b> (1% to 10%): Febrile neutropenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Bone marrow suppression with prolonged pancytopenia, aplastic anemia, hypereosinophilia, myelodysplastic syndrome</p>
<p><b>Postmarketing reports</b>: Hemolytic anemia, febrile neutropenia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Renal impairment, renal failure</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (28%), anorexia (17%), vomiting (13%), diarrhea (10%)</p>
<p><b>Common</b> (1% to 10%): Constipation, abdominal pain, flatulence</p>
<p><b>Uncommon</b> (0.1% to 1%): Mucositis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (28%), diaphoresis, pruritus</p>
<p><b>Common</b> (1% to 10%): Hyperhidrosis, petechiae, ecchymosis, urticaria</p>
<p><b>Uncommon</b> (0.1% to 1%): Stevens-Johnson syndrome, toxic skin eruption, toxic epidermal necrolysis</p>
<p><b>Rare</b> (less than 0.1%): Alopecia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache</p>
<p><b>Common</b> (1% to 10%): Dizziness, somnolence</p>
<p><b>Uncommon</b> (0.1% to 1%): Depressed level of consciousness, neurological toxicity (including peripheral sensory neuropathy, motor neuropathy (paralysis), polyneuropathy, paraparesis)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Administration site reaction<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Weight loss</p>
<p><b>Uncommon</b> (0.1% to 1%): Tumor lysis syndrome, metabolic acidosis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Edema, tachycardia, myocardial ischemia, peripheral edema</p>
<p><b>Rare</b> (less than 0.1%): Heart failure, arrhythmia, heart murmur, hypotension, thrombosis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, myalgia</p>
<p><b>Uncommon</b> (0.1% to 1%): Muscular weakness, paraparesis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough</p>
<p><b>Common</b> (1% to 10%): Pulmonary interstitial infiltrates (including lung infiltration, interstitial lung disease, pneumonitis and pulmonary fibrosis), abnormal breath sounds, abnormal chest sounds, dyspnea, rales<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Increases in bilirubin, increases in transaminases, jaundice<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (unspecified) (up to 28%)</p>
<p><b>Common</b> (1% to 10%): Bacteremia, cellulitis, localized infection, pneumonia, septic shock, serious infection, opportunistic infection<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Postmarketing reports</b>: Conjunctivitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue, pyrexia, pain</p>
<p><b>Common</b> (1% to 10%): Asthenia, chills, malaise, localized edema, chills<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Postmarketing reports</b>: Secondary malignancies<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Confusion, anxiety, insomnia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What are the new drugs used for multiple sclerosis (MS)?</li>
<li>How quickly does Mavenclad work?</li>
<li>Does Mavenclad cause weight gain?</li>
<li>Does Mavenclad cause hair loss?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Mavenclad (cladribine)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: antimetabolites</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Mavenclad &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Leustatin</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Multiple Sclerosis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cladribine: intravenous solution, oral tablet</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia, thrombocytopenia, anemia, purpura</p><p><b>Common</b> (1% to 10%): Febrile neutropenia</p><p><b>Uncommon</b> (0.1% to 1%): Bone marrow suppression with prolonged pancytopenia, aplastic anemia, hypereosinophilia, myelodysplastic syndrome</p><p><b>Postmarketing reports</b>: Hemolytic anemia, febrile neutropenia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Renal impairment, renal failure</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (28%), anorexia (17%), vomiting (13%), diarrhea (10%)</p><p><b>Common</b> (1% to 10%): Constipation, abdominal pain, flatulence</p><p><b>Uncommon</b> (0.1% to 1%): Mucositis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (28%), diaphoresis, pruritus</p><p><b>Common</b> (1% to 10%): Hyperhidrosis, petechiae, ecchymosis, urticaria</p><p><b>Uncommon</b> (0.1% to 1%): Stevens-Johnson syndrome, toxic skin eruption, toxic epidermal necrolysis</p><p><b>Rare</b> (less than 0.1%): Alopecia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache</p><p><b>Common</b> (1% to 10%): Dizziness, somnolence</p><p><b>Uncommon</b> (0.1% to 1%): Depressed level of consciousness, neurological toxicity (including peripheral sensory neuropathy, motor neuropathy (paralysis), polyneuropathy, paraparesis)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Administration site reaction<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Weight loss</p><p><b>Uncommon</b> (0.1% to 1%): Tumor lysis syndrome, metabolic acidosis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Edema, tachycardia, myocardial ischemia, peripheral edema</p><p><b>Rare</b> (less than 0.1%): Heart failure, arrhythmia, heart murmur, hypotension, thrombosis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, myalgia</p><p><b>Uncommon</b> (0.1% to 1%): Muscular weakness, paraparesis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough</p><p><b>Common</b> (1% to 10%): Pulmonary interstitial infiltrates (including lung infiltration, interstitial lung disease, pneumonitis and pulmonary fibrosis), abnormal breath sounds, abnormal chest sounds, dyspnea, rales<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Increases in bilirubin, increases in transaminases, jaundice<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (unspecified) (up to 28%)</p><p><b>Common</b> (1% to 10%): Bacteremia, cellulitis, localized infection, pneumonia, septic shock, serious infection, opportunistic infection<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Postmarketing reports</b>: Conjunctivitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue, pyrexia, pain</p><p><b>Common</b> (1% to 10%): Asthenia, chills, malaise, localized edema, chills<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Postmarketing reports</b>: Secondary malignancies<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Confusion, anxiety, insomnia<sup>[Ref]</sup></p><p id="ref_1">1. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What are the new drugs used for multiple sclerosis (MS)?</li>
<li>How quickly does Mavenclad work?</li>
<li>Does Mavenclad cause weight gain?</li>
<li>Does Mavenclad cause hair loss?</li>
</ul><h2>More about Mavenclad (cladribine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: antimetabolites</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Mavenclad &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Multiple Sclerosis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>